Background Dendritic cells (DC) can exert powerful immune stimulatory as well as regulatory functions and are therefore important tools for therapeutic strategies. Dexamethasone (Dex) was previously shown to inhibit DC maturation and to induce regulatory properties both in vitro and in vivo. Here we investigated the immunoregulatory role of DexDC in two different rat acute rejection models of kidney transplantation. Methods Rat DC were generated from BN and DA bone marrow in the presence of the corticosteroid, Dex. The function of Dex-modulated DC was analysed in vitro and in vivo, using a BN to LEW and a DA to LEW renal transplantation model in the absence of other forms of immunosuppression. T cells of transplanted rats were isolated and restimulated with donor mature DC (either LPS or CD40L activated). T cell responsiveness was analysed by proliferative capacity and IFN-γ production. Results Stimulation of Dex-modulated rat DC with LPS resulted in normal IL-10 production, whereas synthesis of IL-12 was completely impaired. In accordance, the capacity of LPS-DexDC to stimulate T cell activation was decreased. In both renal transplantation models, treatment with donor-derived LPS-DexDC induced a significant donor-specific T cell hyporesponse. However pre-treatment did not result in a prolonged graft survival. Conclusions In two fully mismatched kidney transplantation models, donor-derived LPS-DexDC induce a donor-specific T cell hyporesponse. However, in this setting allograft survival was not improved, suggesting an important role for T cells with indirect alloreactivity. Understanding the underlying mechanism involved in the rejection process will improve the development of a cell-based immunotherapy.
Introduction
Organ transplantation is one of the most important therapies for end stage organ failure. In the past, immunosuppressive therapy has led to significant improvement in short term survival rates for solid organ allografts. Unfortunately, the use of nonspecific immunosuppression has many adverse side-effects like an increased rate of malignancy and infections [1, 2] . To prevent these side-effects and to improve transplantation outcome, the development of new treatment strategies is necessary. In this respect, development of a therapy, which can induce donor-specific tolerance in the absence of continuous immunosuppression, is the ultimate goal in transplantation research. Dendritic cells (DC) are bone marrow-derived antigen presenting cells (APC) and have the potential to induce both immunity and tolerance, and are therefore a good candidate for cell-based therapy. Under steady-state conditions immature DC (iDC) have the capacity to internalise antigens. In the presence of pathogens, DC mature and acquire the capacity to induce an immunogenic response. In contrast, when self antigens are endocytosed in the absence of danger signals, DC induce a tolerogenic response [3, 4] . Previous studies have indeed shown that DC inducing tolerogenic responses are phenotypically immature or semi-immature [5] . The effect of iDC as a cellular treatment to induce transplant tolerance has been studied in different transplantation models [6] . Treatment of recipients with donor-derived iDC induced allogeneic T cell hyporesponsiveness and prolonged allograft survival in heart allograft models [7, 8] . These studies indicate that donor-derived iDC can modulate recipient's immune response. Since iDC can easily mature upon danger signals, there is a risk that, once injected into the recipient, donor-derived iDC will mature. Matured donor-derived DC may subsequently interfere or even counteract with tolerance induction. It may therefore be important to use donor-derived DC, which are blocked in the maturation process. Various compounds including Dexamethasone (Dex), IL-10, and Vitamin D 3 can influence the maturation status of DC and these modulated DC were strongly hampered in their T cell stimulatory capacity [9] [10] [11] [12] [13] [14] . Different modes of activation, including proinflammatory cytokines, LPS or CD40L, demonstrated a hampered upregulation of MHC and co-stimulatory molecules on Dex-treated DC (DexDC) [9, 10] . In addition, stimulated DexDC secrete reduced levels of proinflammatory cytokines, such as IL-6, IL-1β, IL-12 and TNF-α [9, 10, 15, 16] . Importantly, secretion of the antiinflammatory cytokine IL-10 was shown to be increased. As a consequence, DexDC are poor stimulators of allogeneic T cells [9, 10] . The in vivo regulatory properties of modulated DC have been studied in various transplantation models. Contrasting data have been published concerning DC engineered to express IL-10 and TGF-β, demonstrating either their capacity to prolong renal allograft survival [17] or to exacerbate allogeneic heart rejection [18] . In case of Vitamin D 3 -treated donor-derived DC it has been shown that allogeneic skin transplants survive longer when recipients are treated with these modulated DC [19] . The effect of Dexamethasone-treated donor-derived DC (DexDC) on transplant survival has been studied more widely in mouse and rat models. Alternatively activated DC (LPSstimulated DexDC) prolonged transplant survival in a fully mismatched mouse model [20, 21] . In rats, even more pronounced results were obtained using a semi-allogeneic transplantation model and applying DexDC in combination with CTLA4-Ig and cyclosporin [22] . It was shown that donor DC were not successful in graft prolongation and also that the CTLA4-Ig treatment was of critical importance. This suggests a contribution of re-presentation of injected cells and the necessity to control the indirect pathway of allorecognition. In the present study we investigated the regulatory properties of donor-derived LPSDexDC when applied in two different rat models of acute renal allograft rejection. We found that LPS-DexDC induced a donor-specific T cell hyporesponsiveness. However, in the absence of other immunosuppressive treatment, this did not result in prolonged graft survival. To improve DC-based therapies, it is important to understand the mechanisms involved in this rejection process.
Materials and Methods

Animals
Seven to twelve-week-old male Brown Norway (BN; RT1 n ), Dark Agouti (DA; RT1 a ) rats were used as donors and Lewis (LEW; RT1 l ) rats were used as recipients. Rats were purchased from Harlan (Horst, the Netherlands). Animals had free access to water and standard rat chow. Animal care and experimentation were performed in accordance with the local committee of animal experiments of the Leiden University Medical Center.
Generation of rat dendritic cells
Bone marrow (BM) was isolated from tibias and femurs from BN or DA rats by flushing the bones with medium. DC were generated from BM as previously described [23] . Briefly, BM was cultured at a density of 1.5x10 6 cells per well in 3 ml of RPMI 1640 (Invitrogen, Breda, the Netherlands) containing 10% heat-inactivated FCS (BioWhittaker, Vervier, Belgium), penicillin/streptomycin (Gibco), Fungizone (Gibco), β-Mercaptoethanol (50 μM, Merck, Darmstadt, Germany), L-Glutamine (2 mM, Gibco), rat GM-CSF (2 ng/ml, Invitrogen), rat IL-4 (5 ng/ml, Invitrogen) and human Flt3L (50 ng/ml, kindly provided by Amgen) in 6 wells plates (Costar, Cambridge, MA). At day 2 and 4 medium was replaced by fresh medium containing the cytokines. For the generation of DexDC, 10 -6 M dexamethasone (Dex, Pharmacy LUMC, Leiden, the Netherlands) was added to the culture at day 4. At day 7 non-adherent and semi-adherent cells were harvested and activated with LPS (500 ng/ml, Salmonella Typhosa, Sigma, St. Louis, MO, USA) or CD40L, using L-rCD40L [23] or L-orient as a negative control. Cells were plated in new 6 well plates at a density of 1.5x10 6 cells/well in the presence of GM-CSF (2 ng/ml), IL-4 (5 ng/ml) and Flt3L (50 ng/ml) and stimulated for 24 hours.
Kidney transplantation
LEW recipients were injected i.v. with PBS (untreated recipients) or 5x10 6 LPSstimulated DC. Seven days after DC infusion kidney transplantations were performed under isoflurane anesthesia. The left kidney from the donor was perfused using cold University of Wisconsin solution and kept on ice. The left kidney from the recipient was removed and the donor kidney was transplanted in situ. A patch of the donor aorta and the inferior vena cava were anastomosed to the recipient donor aorta and inferior vena cava, respectively. The donor urether was anastomosed end-to-end to the urether of the recipient. Finally the native right kidney was removed. Postoperatively, the recipients received 1 mg/kg body weight of Temgesic (buprenorphine-hydrochlorid; Schering-Plough B.V., Amstelveen, the Netherlands) s.c. for pain relief. Blood samples were collected every other day by tail vein puncture and sera were stored at -80°C. Rats were placed in metabolic cages every other day to collect urine samples. Recipients were sacrificed when low amounts (<2.5 ml) urine was produced o/n. Sera and kidneys were collected. Creatinine levels were measured in sera.
Cytokine analysis by ELISA
Cytokines were measured in the supernatant of the activated cells. ELISAs detecting Rat IL-12p40, (Invitrogen), rat IL-10 (R&D Abingdon, UK) or rat IFN-γ (BD, Breda, the Netherlands) were performed following the instructions provided by the supplier.
Allogeneic Mixed Lymphocyte Reaction
LEW T cells were isolated from splenocytes by depletion of κ light chain and MHC class II expressing cells. In all cases, T cells were isolated from individual rats and tested individually in independent experiments as indicated. Briefly, splenocytes were incubated in phosphate buffered saline containing 2% heat inactivated FCS (BioWhittaker) and 2.5 mM EDTA and HIS8 (anti-κ light chain) and OX6 (anti-MHC class II) (kindly provided by Dr. E. de Heer, LUMC, the Netherlands). Where indicated NKR-P1A expressing cells were depleted by adding NK3.2.3 (kindly provided by Dr. P. Kuppen, LUMC, the Netherlands) to the buffer. After incubation, cells were washed and subsequently incubated with goat anti-mouse beads (Polysciences Inc, Warrington, PA, USA). The negative population was obtained using a magnet (BD) and used as responder cells. Irradiated (50Gy) stimulator cells were added in increasing doses to 1x10 5 
Flow cytometric analysis
LPS-stimulated DC were stained with CD86 (BD, Breda, the Netherlands) and MHC class II (OX 6) (kindly provided by Dr. E. de Heer, LUMC, Leiden the Netherlands). Expression levels were detected by making use of a phycoerythrin-conjugated goat anti-mouse Ig (Dako, Glostrum, Denmark). The enriched T cell population was stained with antibodies directed to TCR (R73), CD4 (ER2), CD8 (OX8) (all kindly provided by Dr. E. de Heer, LUMC, the Netherlands) and NKR-P1A (NK3.2.3 IgG2b isotype) (kindly provided by Dr. P. Kuppen, LUMC, the Netherlands). Binding was visualized using phycoerythrin-conjugated goat anti-mouse Ig (Dako, Glostrum, Denmark), or fluorescein isothiocyanate-conjugated goat anti-mouse IgG2b (Southern Biotechnology, Birmingham, Alabama, USA). The cells were assessed for fluorescence using a FACS Calibur (BD, Mountain View, CA). Data analysis was performed using WinMDI 2.8 software.
Statistical analysis
Statistical significant differences were determined with Graphpad Prism® using the Mann-Whitney test. Differences were considered significant when p<0.05.
Results
Dexamethasone blocks the maturation process of bone marrowderived rat dendritic cells
To investigate whether Dex also blocks maturation of rat DC, rat bone marrow-derived DC from BN and DA rats were generated and cultured in the absence or presence of Dex, resulting in CtrDC or DexDC respectively. At day 7, cells were washed and stimulated with LPS, in the absence of Dex, and expression levels of CD86 and MHC class II molecules were determined as well as the cytokine profile. Upon LPS-stimulation, DexDC show reduced levels of CD86 and MHC class II molecule expression compared to CtrDC (Fig 1A) . Both BN-and DA-derived CtrDC produced IL-12 and IL-10 upon LPS activation. Stimulation of DexDC with LPS demonstrated that these DC secrete similar levels of IL-10 compared to non-treated DC. However, for both DC derived from BN or DA origin, treatment with Dex completely prevented the LPS-induced IL-12 production (Fig. 1B&C) . Similarly, also CD40L-induced IL-12 was completely prevented (data not shown). The T cell stimulatory capacity of CtrDC and DexDC was studied by culturing allogeneic T cells in the presence of increasing amounts of CtrDC or DexDC. LPS activation of CtrDC derived from BN and DA origin showed a strongly increased capacity to induce LEW-derived T cell proliferation ( Fig. 2A) and IFN-γ production (Fig. 2B) . In line with the altered cytokine production, both BN and DA derived LPS-DexDC were shown to be impaired in the capacity to stimulate allogeneic T cells (Fig. 2) .
LPS-DexDC treatment does not prolong graft survival in a fully mismatched kidney transplantation model
The finding that LPS-DexDC were hampered in their capacity to stimulate T cells, prompted us to investigate the immunoregulatory potential of LPS-DexDC as a cellular therapy in transplantation. We used two rat models of acute cellular renal allograft rejection. LEW recipients were pretreated with PBS or 5x10 6 donor DC, 7 days prior to orthotopic transplantion of either a BN or DA kidney. To circumvent potential interference with the induction of regulatory processes, transplantation was performed in the absence of any other form of immunosuppression. In both models, rejection occurred approximately 6 days after transplantation (for BN kidney at days 6,6,6,7,6, for DA kidney at days 6,6,6,6). Pretreatment with LPS-DexDC did not result in a prolonged graft survival (for BN kidney recipients at day 6,7,7,7,7, for DA kidney recipients at day 8, 6, 6, 6) , as also demonstrated by a similar increase of serum creatinine levels in both groups (Fig. 3A) . Histological analysis of renal tissue derived from LPS-DexDC treated recipients at the time of rejection demonstrated strong cellular influx and typical signs of acute rejection (Fig. 3B) . In the DA to LEW model, LPS-CtrDC were used as a control cellular treatment, and as expected did also not result in prolonged graft survival (rejection was observed at day 4,6 after transplantation). 
LPS-DexDC induce allogeneic T cell hyporesponsiveness in vivo
Although no effects on graft survival were observed, the fact that no other immunosuppression was used offered the possibility to directly investigate the in vivo regulatory effects of LPS-DexDC. T cells were isolated from spleen of renal allograft recipients and investigated for functional responsiveness to donor antigens. Restimulation of recipient T cells with LPS-matured donor-derived DC showed that the proliferative response of LPS-DexDC pretreated animals was reduced compared to PBS treated recipients (Fig. 4A) . Although the proliferative responses were low in the DA to LEW condition, it clearly showed that Dex treatment prevented the specific priming observed with pretreatment with mature DC. Experiments using human DexDC previously demonstrated that these cells especially induced donor-specific hyporesponsiveness at the level of IFN-γ production [24] . Restimulation with LPS-matured donor DC induced high levels of IFN-γ production by recipient T cells derived from PBS treated allogeneic transplantations. In both models, this production is much higher compared to naïve T cells, demonstrating that the transplantation has primed the immune system (Fig. 4B) . Pretreatment with LPSDexDC significantly reduced and almost completely prevented the production of IFN-γ by these recipient T cells. In contrast, pretreatment with LPS-CtrDC in the DA to LEW model even further increased levels of IFN-γ production compared to PBS treated recipients (Fig. 4B) . To exclude that observed IFN-γ hyporesponsiveness was due to a general immunosuppression, we investigated the effect of stimulation with third party DC. LPSstimulated DC of AO origin induced comparable levels of IFN-γ production in T cells derived from PBS treated and LPS-DexDC treated transplant recipients (Fig. 4C) , demonstrating that induction of T cell hyporesponsiveness was donor specific. Previously we have shown that CD40L-stimulated DC have the capacity to induce a much stronger IFN-γ response compared to LPS-stimulated DC [23] . Comparable to the LPS-stimulated DC condition, T cells derived from PBS treated recipients showed Figure 5 . T cell hyporesponse remains after CD40L-stimulated donor DC. Enriched T cells derived from naïve untransplanted rats (dotted), from PBS treated (white), LPS-CtrDC (gray) or LPS-DexDC (black) treated transplant recipients at the time of rejection were cultured with CD40L-stimulated donor-derived DC and IFN-γ levels were measured in supernatant by ELISA. Results shown are the mean ± SD of four independent experiments, except for the LPS-CtrDC group (n=2). Figure 6 . Increased NKR-P1A + population in recipient's spleen at time of rejection does not influence the IFN-γ response. Spleen was taken from BN and DA kidney recipients when rejection was observed and depleted from B cells and MHC class II + cells. A) Enriched cells derived from PBS treated (white), LPS-CtrDC (gray) or LPS-DexDC (black) treated recipients were stained for TCR, CD4, CD8 and NKR-P1A expression and detected by flow cytometry. Fold increase of the positive cells in recipient spleen in relation to naïve spleen, derived from untransplanted rats, was calculated, dividing the percentage of stained cells in recipient spleen by the percentage present in naïve spleen. Results shown are the mean ± SD of five independent experiments in BN to LEW model and four independent experiments in DA to LEW model with exception of LPS-CtrDC treated recipients (n=2). B) Enriched T cells derived from naïve rats were stained with TCR (R73) and NKRP-1A (NK3.2.3) and detected by flow cytometry. C) T cell enriched splenocytes derived from LPS-CtrDC or LPS-DexDC treated recipients (non-depleted in gray and NKRP1A depleted in black) were cultured with unstimulated, LPS or CD40L stimulated donor-derived DC. IFN-γ production was measured in supernatant by ELISA. Results shown are mean ± SD of two independent experiments high production of IFN-γ upon culture with CD40L-stimulated DC, whereas T cells derived from LPS-DexDC treated recipients demonstrated only low levels of IFN-γ production in both models (Fig. 5) . Furthermore, T cells derived from LPS-CtrDC treated recipients in the DA to LEW model produced higher levels of IFN-γ compared to T cells derived from PBS treated recipients.
Increased NKR-P1A
+ cells in spleen taken from recipients not involved in IFN-γ response against donor-derived DC Next to T cells, activated NK cells can contribute to the production of IFN-γ [25] . To investigate this contribution, splenocytes were isolated from either naïve LEW rats or recipients of DA or BN kidney allografts and depleted from B cells and MHC class II + cells. Although the T cell composition of transplanted rats only showed minor changes compared to naïve rats, both models showed an increase in the number of cells expressing the NK cells marker NKR-P1A (Fig. 6A) . Double staining with the TCR marker R73 and the expression level of NKR-P1A could be used to identify NK cells (Fig. 6B) .
To determine the contribution of NK cells to the measured IFN-γ production, T cellenriched splenocyte populations were depleted from NKR-P1A ++ cells. IFN-γ levels were measured from the non-depleted T cell population and NKR-P1A depleted (at least 75% depletion of NKR-P1A
++ cells) population after restimulation with donor DC (unstimulated, LPS-or CD40L-stimulated). Both non-depleted and NKR-P1A depleted T cells derived from LPS-CtrDC and LPS-DexDC treated recipients produced similar levels of IFN-γ in all conditions (Fig. 6C) , demonstrating that NK cells do not play a major role in the T cell response detected in DC-treated recipients.
Discussion
In the present study, we investigated the immunoregulatory effect of donor-derived LPS-DexDC on rat kidney allograft survival. In the absence of any other co-treatments, this did not result in a prolonged graft survival in two different models of acute rejection. However, we established that in both models T cells from LPS-DexDC treated recipients were hyporesponsive to donor antigens while maintaining normal response to third party antigens, especially at the level of IFN-γ production. Although increased numbers of NKR-P1A + cells were observed in the spleen following transplantation, these cells did not contribute to the observed IFN-γ production. The presence of immunoregulatory cytokines and the absence of proinflammatory cytokines may be critical for the immunomodulatory effect of DC [5] . We observed that under all conditions, Dex treatment completely prevented the production of IL-12, without affecting IL-10 production. The level of IL-12 production is dependent on the mode of DC activation, and is superior upon CD40L activation. Interestingly, this is also reflected by the level of IFN-γ production when these CD40L-activated DC are used in a MLR. Moreover, we found that both in vitro and upon ex vivo restimulation, DC from DA origin, characterized by higher levels of IL-12, are also stronger inducers of IFN-γ production during MLR. Previously we have shown that rat DC produce IL-10 after LPS stimulation, in contrast to CD40L-stimulated DC [23] . This inability to produce IL-10 upon CD40L activation was also observed in DexDC. Therefore, in our in vivo experiments, we made use of LPS-stimulated DexDC, that do produce IL-10. Administration of LPS-DexDC to recipients 7 days prior to transplantation did not result in prolonged transplant survival. Interestingly, we observed a significant induction of T cell hyporesponsiveness in recipients treated with LPS-DexDC in contrast to PBS treated recipients. In addition, T cells derived from recipients treated with LPS-CtrDC demonstrated an increased response to donor antigens. This confirms that Dex treatment is essential for the induction of donor-specific hyporesponsiveness and prevents priming of the immune system. Although LPS-DexDC possess the capacity to regulate T cell responses, in the present setting this treatment was not sufficient to downregulate all processes involved in renal transplant rejection. Antigen presentation in the transplantation setting can occur through the direct and indirect pathway. Pretreatment with donor cells and restimulation with donor-DC in MLR will both only involve the direct pathway and it is therefore tempting to speculate that the observed rejection might be caused by T cells with indirect allo-specificity. Administration of donor-derived iDC prior to transplantation has been demonstrated to induce prolonged graft survival in several models [7, 8, 22, 26, 27] . Only a few studies investigated kidney transplantation survival upon DC treatment in rat models [22, 27] . DexDC have been shown to have the capacity to induce tolerance and mediate immune regulation via the indirect pathway and prolong kidney survival [22] . The latter study was performed with a semi-allogeneic rat model, in which LEW rats were treated with Dex-modulated (LEW x AUG) F1-derived DC and received kidneys derived from AUG rats. Recipients were co-treated with cyclosporin A and CTLA4-Ig and a unilateral kidney transplantation procedure was performed. It was shown that donor DC were not successful in graft prolongation and also that the CTLA4-Ig treatment was of critical importance. These experiments clearly demonstrate the importance in regulating the indirect pathway. In two fully mismatched transplantation models, where no additional co-treatment is given to recipients, we confirmed that regulation via the direct pathway is not sufficient. We think this might be a suitable model to investigate additional mechanisms involved in the rejection of allografts. To investigate whether Dex-DC pretreatment might affect humoral immunity, we measured development of donor-specific anti-MHC antibodies in the transplanted rats, pre-treated with Dex-DC or not. Strong antibody responses were detected in both groups, and there was no difference in the quantitative development of IgG responses between the two groups (data not shown). NKR-P1A expressing cells were shown to be increased in the spleen of all recipients and NKR-P1A has been show to be a marker for NK cells [28] . Activated NK cells produce cytokines, such as IFN-γ, TNF-α or IL-5 and these signals can promote the generation of alloreactive T cells and are therefore associated with graft rejection [29, 30] . However, we show that the NKR-P1A ++ population present in the spleen at the time of rejection did not contribute to the IFN-γ response against donor-derived DC. In conclusion, despite the induction of donor-specific hyporesponsiveness by a single treatment of donor-derived LPS-DexDC, no prolonged graft survival was observed in two fully mismatched rat kidney transplantation models. The latter may be expected in such a stringent model, but this model provides the opportunity to unravel all mechanisms involved in the response on DC-mediated cellular therapy in detail. It will be important to understand the mechanisms involved in the remaining rejection process to improve the effectiveness of such a cell-based therapy.
